Author information
1
Rory Myers College of Nursing, New York University, 433 First Avenue 7th Floor, New York, New York, 10010; Center for Drug Use and HIV Research, New York, New York. Electronic address: aj924@nyu.edu.
2
Center for Drug Use and HIV Research, New York, New York; Icahn School of Medicine at Mount Sinai Beth Israel, Baird Hall, 350 East 17th St 19th Floor, New York, New York, 10003.
3
Rory Myers College of Nursing, New York University, 433 First Avenue 7th Floor, New York, New York, 10010.
4
Rory Myers College of Nursing, New York University, 433 First Avenue 7th Floor, New York, New York, 10010; Center for Drug Use and HIV Research, New York, New York.
Abstract
There is increasing recognition of the importance of the distinction between efficacy and effectiveness research in the design, conduct, and evaluation of interventions and program outcomes. There is a concurrent increase in the application of systematic reviews and meta-analyses. These two lines of inquiry are only beginning to meet. There is an emerging need for systematic reviews and meta-analyses to account for differences in degrees to which included studies reflect either efficacy and effectiveness designs. Based on on-going work on a formal systematic review of the hepatitis C virus care continuum, this paper describes and discusses the rationale for, and how the PRECIS-II instrument can be used on, and modestly adapted to, studies included in the systematic review examining the extent to which studies include elements of efficacy or effectiveness, or a combination of the two. We also highlight that use of such an instrument may have general applicability to and value in the conduct of systematic reviews and meta-analysis.